CyFlow CD8a Alexa Fluor 488
| 品番 | AP888121 | ||
|---|---|---|---|
| 抗体名 | Anti-Ms CD8A AF 488,53-6.7 | ||
| 包装単位 | 0.1 mg | ||
| 濃度 | 0.5 mg/ml | ||
| 容量 | 0.2 ml | ||
| 関連製品 (アイソタイプコントロール) |
- | ||
| 反応性|交差吸着 | Mouse | レーザー | Blue |
| 抗原 | CD8a, T8, Leu2 | 最大蛍光波長 | 519 nm |
| クローン | 53-6.7 | 最大励起波長 | 495 nm |
| ホスト | Rat | 標識/Format | Alexa Fluor™ 488 |
| アイソタイプ | IgG2a | 研究分野 | Immunophenotyping | MHC |
| クローナリティ | monoclonal | 用途 | Flow cytometry |
Anti-Ms CD8A AF 488,53-6.7
特異性
The rat monoclonal antibody 53-6.7 recognizes mouse CD8a antigen, a 32-34 kDa α chain of the CD8 antigen.
抗原情報
The CD8a (CD8 α) subunit of CD8 T cell coreceptor is expressed in CD8 α/β heterodimers on majority of MHC I-restricted conventional T cells and thymocytes and in CD8 α/α homodimers on subsets of memory T cells, intraepithelial lymphocytes, NK cells, macrophages and dendritic cells. Regulation of CD8 beta level on T cell surface seems to be an important mechanism to control their effector function. Assembly of CD8 α/β but not α/α dimers is connected with formation or localization to the lipid rafts. Recruiting triggered TCR complexes to these membrane microdomains as well as affinity of TCR to MHC I is modulated by CD8, thereby affecting the functional diversity of the TCR signaling.
利用方法
The reagent is designed for Flow Cytometry analysis. Suggested working usage is 0.5 µg/ml. Indicated dilution is recommended starting point for use of this product, but working concentrations should be validated by the investigator.
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Bouwer HG, Alberti-Segui C, Montfort MJ, Berkowitz ND, Higgins DE: Directed antigen delivery as a vaccine strategy for an intracellular bacterialpathogen. Proc·Natl·Acad·Sci·USA. 2006·Mar·28; 103(13):5102‑7. <·PMID:·16549792·>
• Grabbe S, Varga G, Beissert S, Steinert M, Pendl G, Seeliger S, Bloch W, Peters T, Schwarz T, Sunderkötter C, Scharffetter-Kochanek K: Beta2 integrins are required for skin homing of primed T cells but not for priming naive T cells. J·Clin·Invest. 2002·Jan; 109(2):183‑92. <·PMID:·11805130·>
• Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, Azuma Y, Kanai C, Moriizumi E, Nomura T, Nakamura T, Sakaguchi S: Distinct contribution of IL‑6, TNF‑alpha, IL‑1, and IL‑10 to T cell‑mediated spontaneous autoimmune arthritis in mice. J·Clin·Invest. 2004·Aug; 114(4):582‑8. <·PMID:·15314695·>
• Kamimura D, Sawa Y, Sato M, Agung E, Hirano T, Murakami M: IL‑2 in vivo activities and antitumor efficacy enhanced by an anti‑IL‑2 mAb. J·Immunol. 2006·Jul·1; 177(1):306‑14. <·PMID:·16785526·>
• Ko SY, Ko HJ, Chang WS, Park SH, Kweon MN, Kang CY: alpha‑Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J·Immunol. 2005·Sep·1; 175(5):3309‑17. <·PMID:·16116223·>
• Ledbetter JA, Herzenberg LA: Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens. Immunol·Rev. 1979; 47:63‑90. <·PMID:·398327·>
• Ledbetter JA, Rouse RV, Micklem HS, Herzenberg LA: T cell subsets defined by expression of Lyt‑1,2,3 and Thy‑1 antigens: Two‑parameter immunofluorescence and cytotoxicity analysis with monoclonal antibodies modifies current views. J·Exp·Med. 1980·Aug·1; 152(2):280‑95. <·PMID:·6156984·>
• Mochimaru H, Usui T, Yaguchi T, Nagahama Y, Hasegawa G, Usui Y, Shimmura S, Tsubota K, Amano S, Kawakami Y, Ishida S: Suppression of alkali burn‑induced corneal neovascularization by dendritic cell vaccination targeting VEGF receptor 2. Invest·Ophthalmol·Vis·Sci. 2008·May; 49(5):2172‑7. <·PMID:·18263815·>
• Takahashi K, Nakata M, Tanaka T, Adachi H, Nakauchi H, Yagita H, Okumura K: CD4 and CD8 regulate interleukin 2 responses of T cells. Proc·Natl·Acad·Sci·USA. 1992·Jun·15; 89(12):5557‑61. <·PMID:·1608966·>
Available Safety Data Sheets
CyFlow™ monoclonal antibodies SDS CA EN